TGFB1 and Hepatic fibrosis: Our results show that neratinib treatment significantly ameliorates both stages of liver fibrosis mice, as confirmed by the reductions in α-SMA expression, collagen deposition, and other fibrogenic markers (TIMP-1, PDGFR-β, and TGF-β) in liver tissues.